2. Search Result
Search Result
Results for "

111In

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

1

Screening Libraries

3

Biochemical Assay Reagents

9

Peptides

1

Inhibitory Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-NP111
    Highly purified Type V collagen, from mouse intestine

    Mouse Type V collagen, immunization grade

    		 MMP Inflammation/Immunology
    Highly purified Type V collagen, from mouse intestine (Mouse Type II collagen, immunization grade) is an immune grade collagen derived from mouse intestine, which can stimulate the animal's immune system to produce specific antibodies against this collagen. Collagen is also a substrate for hydrolysis by MMPs .
    Highly purified Type V collagen, from mouse intestine
  • HY-W053583
    Tetraxetan
    1 Publications Verification

    DOTA

    		 Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Cancer
    Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
    Tetraxetan
  • HY-P991577
    DS-8895

    DS-8895A

    		 Ephrin Receptor Cancer
    DS-8895(DS-8895A) is an anti-EphA2 monoclonal antibody with specific binding to EphA2 receptors and EphA2-expressing cells. DS-8895, when conjugated with 89Zr, 111In, or 125I, supports molecular imaging of EphA2 expression in xenograft models. DS-8895 allows noninvasive measurement of EphA2 expresssion in tumors in vivo. .
    DS-8895
  • HY-157977
    DOTA-GA-maleimide

    		Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) MMP Cancer
    DOTA-GA-maleimide is a bifunctional chelator with protein conjugation and radiometal chelation capabilities. DOTA-GA-maleimide forms stable complexes with 111In and conjugates with proteins via maleimide chemistry. DOTA-GA-maleimide conjugates with LFn, enabling 111In radiolabeling of LFn through direct or pre-labeling strategies. Radiolabeled LFn is applicable to MMP activity imaging studies. DOTA-GA-maleimide is used in cancer research .
    DOTA-GA-maleimide
  • HY-173374
    DOTAGA-FAP-2286-ALB

    		FAP Drug Derivative Cancer
    DOTAGA-FAP-2286-ALB is a derivative of Rofapitide tetraxetan (HY-147057). DOTAGA-FAP-2286-ALB is a selective fibroblast activation protein (FAP) inhibitor with an IC50 value of 67.5 nM. DOTAGA-FAP-2286-ALB enhances tumor retention via albumin interaction, prolonging blood circulation and improving radiometal complex stability (e.g., with 111In and 225Ac). DOTAGA-FAP-2286-ALB is promising for research of radionuclide therapy (TRT) of FAP-positive solid tumors .
    DOTAGA-FAP-2286-ALB
  • HY-P10239
    Tyr3-Octreotate

    		Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs) Cancer
    Tyr3-Octreotate is a ligand for somatostatin receptor subtype 2 (sst2), with an IC50 value of 1.3 nM against sst2 when labeled with [ 111In-DTPA], and an IC50 value of 1.6 nM against sst2 when labeled with [ 90Y-DOTA]. Radiolabeled Tyr3-Octreotate generates cell-associated radioactivity, and acts as both a tumor growth inhibitor and a tumor cytotoxic agent. When radiolabeled with 177Lu or 90Y, Tyr3-Octreotate serves as a peptide receptor radionuclide therapy (PRRT) analog. Tyr3-Octreotate can be used in studies related to pancreatic tumors .
    Tyr3-Octreotate
  • HY-P11339
    c-RGD-SH

    		Integrin Cancer
    c-RGD-SH is a ligand for integrin αvβ3 (Integrin αvβ3). Conjugation of c-RGD-SH with core-crosslinked polymeric micelles (CCPM) enables the synthesis of a bimodal nanoprobe, which can be labeled with Cy7 and 111In for SPECT and NIRF imaging of tumors .
    c-RGD-SH
  • HY-P10896
    NOTA-P2-RM26

    		Bombesin Receptor Cancer
    NOTA-P2-RM26 is an antagonist of Bombesin (HY-P0195) analogs, and the gastrin-releasing peptide receptor (GRPR/BB2) is a molecular target for prostate cancer visualization. NOTA-P2-RM26 is labeled with 111In and 68Ga for prostate cancer imaging studies using PET and SPECT/CT .
    NOTA-P2-RM26
  • HY-P2022
    Pentetreotide

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    Pentetreotide is a diethylenetriaminopentaacetic (DTPA) conjugate of Octreotide (HY-P0036). Pentetreotide is a somatostatin analog that, when labeled with 111In, can be used for nuclear medicine imaging. Somatostatin receptor scintigraphy with Pentetreotide is effective in visualizing neuroendocrine tumors, and its metastasis .
    Pentetreotide
  • HY-W053583R
    Tetraxetan (Standard)

    DOTA (Standard)

    		 Biochemical Assay Reagents Reference Standards Radionuclide-Drug Conjugates (RDCs) Cancer
    Tetraxetan (Standard) is the analytical standard of Tetraxetan (HY-W053583). This product is intended for research and analytical applications. Tetraxetan (DOTA) is a macrocyclic chelating agent. Tetraxetan can form stable coordination complexes with a variety of metal ions (e.g., 68Ga, 111In, 177Lu). Tetraxetan can be conjugated with targeting molecules (e.g., RGD peptide, folic acid) to enable the complex to target specific biomolecules or cells. Tetraxetan can be used for imaging studies of tumors, including melanoma and folate receptor-positive tumors (e.g., cervical cancer) .
    Tetraxetan (Standard)
  • HY-158118
    Lys(CO-C3-p-I-Ph)-OMe

    		DNA-PK Cancer
    Lys(CO-C3-p-I-Ph)-OMe is a pharmacokinetic modifier (PK modifier) that can improve the PK properties of PSMA ligand molecules (such as Ac-PSMA-trillium). Lys(CO-C3-p-I-Ph)-OMe can increase the residence time of Ac-PSMA-trillium in plasma by increasing its binding capacity to albumin. Lys(CO-C3-p-I-Ph)-OMe also reduces salivary gland absorption of Ac-PSMA-trillium, potentially extending its half-life. Ac-PSMA-trillium is a suitable PSMA-targeting compound that has different biological applications after modification with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
    Lys(CO-C3-p-I-Ph)-OMe
  • HY-P11339A
    c-RGD-SH TFA

    		Integrin Cancer
    c-RGD-SH TFA is an Integrin αvβ3 ligand. c-RGD-SH TFA conjugated with core-crosslinked polymeric micelles (CCPM) can be used for synthesis a dual modality nanoparticle probe, and this probe labeled with both Cy7 and 111In can be used for SPECT and NIRF imaging of tumor .
    c-RGD-SH TFA
  • HY-W738256
    Maleimide-DTPA

    MDTPA

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    Maleimide-DTPA (MDTPA) is a monoreactive DTPA derivative (MDTPA) with maleimide group as peptide binding site, which can be combined with radionuclides to prepare radionuclide conjugates (RDC). Maleimide-DTPA can chelate indium-111 (111In) and label peptides and peptides with indium-111. For example, it has high stability when combined with OST7 incubated in human serum, which is better than cyclic cDTPA. Maleimide-DTPA is a good material for medical imaging or treatment.
    Maleimide-DTPA
  • HY-158125
    PSMA binder-2

    		PSMA Cancer
    PSMA binder-2 is a ligand for PSMA and can be used to synthesize Ac-PSMA-trillium. Ac-PSMA-trillium is a suitable PSMA-targeting compound with improved PSMA binding properties and pharmacokinetic properties. PSMA ligands have different biological applications after being modified with different radioactive isotopes. If labeled with 111In, it can be used as DOTA chelating agent and imaging agent. Or labeled with 225Ac as a Macropa chelator for targeted radionuclide therapy (TRT) in the study of metastatic castration-resistant prostate cancer (mCRPC) .
    PSMA binder-2
  • HY-P10012
    Pendetide

    GYK-DTPA

    		 Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Cancer
    Pendetide is a chelating agent, can be conjugated with Indium (111In) Capromab for further diagnostic use. Capromab pendetide is a FDA-approved imaging agent for the detection of soft tissue metastases in prostate carcinoma . Pendetide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Pendetide
  • HY-159771
    FAP6-19

    		FAP Cancer
    FAP6-19 is a fibroblast activation protein (FAP) targeting radioligand with a Kd of 18.2 nM. FAP6-19 selectively delivers therapeutic radioactive nuclides (such as 177Lu) to the tumor site by targeting the overexpressed FAP protein in the tumor microenvironment, achieving precise killing of cancer cells while minimizing radiation damage to healthy tissues. FAP6-19 exhibits extremely high total cellular uptake and good intracellular retention ability in HT1080 cells. After being labeled with 111In, FAP6-19 produced extremely high tumor/kidney and tumor/liver dose ratios in the mouse model with 4T1 tumors. FAP6-19 can be used in the research of solid tumors expressing FAP.
    FAP6-19
  • HY-155446
    di-DTPA-LTL

    		Hapten Inflammation/Immunology Cancer
    di-DTPA-LTL is a bivalent hapten based on tyrosine-containing polypeptide design. di-DTPA-LTL has good hydrophilia and biological distribution. di-DTPA-LTL is labeled with 111In (indium) and 131I (iodine). di-DTPA-LTL achieves tumor radioimmunoimaging in primary colorectal cancer patients with CEA by injecting a fixed low dose (5 mg) of bispecific antibody (anti-CEA x, anti-DTPA) and di-DTPA antigen peptide (labeled 111In) into the patients .
    di-DTPA-LTL
  • HY-P10744
    BQ7859

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    BQ7859
  • HY-P11594
    JMV 7490

    		Neurotensin Receptor Cancer
    JMV 7490 is a highly potent and highly hydrophilic neurotensin receptor NTS1 probe that can be successfully labeled with 68Ga and 111In. JMV 7490 acts as an efflux inhibitor to reduce its efflux in NTS1-positive cancer cells; it also serves as an internalization inducer and is efficiently and continuously internalized by NTS1-positive cancer cells. 111In-radiolabeled JMV 7490 shows persistent uptake in NTS1-positive xenografts in nude mice, but no significant uptake in NTS1-negative xenografts. JMV 7490 can be used for in vivo tracer applications of NTS1-positive tumors and supports related research on colorectal cancer .
    JMV 7490

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: